These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34113694)

  • 1. Analysis of the subsequent treatment of osteoporosis by transitioning from bisphosphonates to denosumab, using quantitative computed tomography: A prospective cohort study.
    Tsuchiya K; Ishikawa K; Kudo Y; Tani S; Nagai T; Toyone T; Inagaki K
    Bone Rep; 2021 Jun; 14():101090. PubMed ID: 34113694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density.
    Genant HK; Engelke K; Hanley DA; Brown JP; Omizo M; Bone HG; Kivitz AJ; Fuerst T; Wang H; Austin M; Libanati C
    Bone; 2010 Jul; 47(1):131-9. PubMed ID: 20399288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis.
    Malluche HH; Davenport DL; Cantor T; Monier-Faugere MC
    Clin J Am Soc Nephrol; 2014 Jul; 9(7):1254-62. PubMed ID: 24948144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Wang H; Liu Y; San Martin J
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab.
    Genant HK; Libanati C; Engelke K; Zanchetta JR; Høiseth A; Yuen CK; Stonkus S; Bolognese MA; Franek E; Fuerst T; Radcliffe HS; McClung MR
    Bone; 2013 Oct; 56(2):482-8. PubMed ID: 23871852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates.
    Miller PD; Pannacciulli N; Malouf-Sierra J; Singer A; Czerwiński E; Bone HG; Wang C; Huang S; Chines A; Lems W; Brown JP
    Osteoporos Int; 2020 Jan; 31(1):181-191. PubMed ID: 31776637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Distal Radius Bone Mineral Density in Osteoporosis Patients Receiving Denosumab, Including Those with Rheumatoid Arthritis and Those Receiving Oral Glucocorticoids.
    Matsuno H
    Drugs R D; 2016 Dec; 16(4):347-353. PubMed ID: 27766589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
    Nakamura Y; Suzuki T; Kato H
    Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis.
    Ebina K; Tsuboi H; Nagayama Y; Kashii M; Kaneshiro S; Miyama A; Nakaya H; Kunugiza Y; Hirao M; Okamura G; Etani Y; Takami K; Goshima A; Miura T; Nakata K; Okada S
    Joint Bone Spine; 2021 Oct; 88(5):105219. PubMed ID: 34020048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significant improvement of bone mineral density by denosumab without bisphosphonate pre-treatment in glucocorticoid-induced osteoporosis.
    Suzuki T; Nakamura Y; Kato H
    Mod Rheumatol; 2018 Sep; 28(5):885-889. PubMed ID: 29251033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in RANKL and TRAcP 5b after discontinuation of denosumab suggest RANKL mediated formation of osteoclasts results in the increased bone resorption.
    Sølling AS; Harsløf T; Jørgensen NR; Langdahl B
    Osteoporos Int; 2023 Mar; 34(3):599-605. PubMed ID: 36543965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Denosumab significantly improves lumbar spine bone mineral density more in treatment-naïve than in long-term bisphosphonate-treated patients.
    Suzuki T; Nakamura Y; Kamimura M; Kato H
    Bone Rep; 2018 Jun; 8():110-114. PubMed ID: 29955629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial.
    Mok CC; Ho LY; Ma KM
    Bone; 2015 Jun; 75():222-8. PubMed ID: 25761434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative computed tomography (QCT) of the forearm using general purpose spiral whole-body CT scanners: accuracy, precision and comparison with dual-energy X-ray absorptiometry (DXA).
    Engelke K; Libanati C; Liu Y; Wang H; Austin M; Fuerst T; Stampa B; Timm W; Genant HK
    Bone; 2009 Jul; 45(1):110-8. PubMed ID: 19345291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone microstructure in healthy men measured by HR-pQCT: Age-related changes and their relationships with DXA parameters and biochemical markers.
    Doi M; Chiba K; Okazaki N; Kondo C; Yamada S; Yokota K; Yonekura A; Tomita M; Osaki M
    Bone; 2022 Jan; 154():116252. PubMed ID: 34743043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of anthropometric parameters and bone size on bone mineral density using volumetric quantitative computed tomography and dual X-ray absorptiometry at the hip.
    Guglielmi G; van Kuijk C; Li J; Meta MD; Scillitani A; Lang TF
    Acta Radiol; 2006 Jul; 47(6):574-80. PubMed ID: 16875335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of peripheral quantitative computed tomography forearm bone density versus DXA in rheumatoid arthritis patients and controls.
    Juhász B; Gulyás K; Horváth Á; Pethő Z; Bhattoa HP; Váncsa A; Szekanecz É; Horváth C; Kocsis J; Horváth Z; Hodosi K; Szántó S; Szűcs G; Szekanecz Z
    Osteoporos Int; 2017 Apr; 28(4):1271-1277. PubMed ID: 27942777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of osteoporosis drug treatments on cortical and trabecular bone in the femur using DXA-based 3D modeling.
    Winzenrieth R; Humbert L; Di Gregorio S; Bonel E; García M; Del Rio L
    Osteoporos Int; 2018 Oct; 29(10):2323-2333. PubMed ID: 29974136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Administration of Denosumab Preserves Bone Mineral Density at the Knee in Persons With Subacute Spinal Cord Injury: Findings From a Randomized Clinical Trial.
    Cirnigliaro CM; La Fountaine MF; Parrott JS; Kirshblum SC; McKenna C; Sauer SJ; Shapses SA; Hao L; McClure IA; Hobson JC; Spungen AM; Bauman WA
    JBMR Plus; 2020 Aug; 4(8):e10375. PubMed ID: 33134767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of denosumab on rheumatic diseases and refractory glucocorticoid-induced osteoporosis: a prospective study.
    Ishida T; Yoshida S; Fujiki Y; Hata K; Kotani T; Takeuchi T
    Arch Osteoporos; 2021 Feb; 16(1):39. PubMed ID: 33624165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.